REFERENCES 

1.     The Eye Disease Prevalence Research Group. Prevalence of Age-Related Macular Degeneration in the United States. Arch Ophthalmol. 2004; 122:564-572.

2.    Prevent Blindness America and National Eye Institute. Vision Problems in the U.S.: Prevalence of Adult Vision Impairment and Age-Related Eye Disease in America. 2002.

3.    Rosenthal BP, et al. Seeing the Whole Picture: Visual Function and Age-Related Macular Degeneration. 2003.

4.    The Eye Disease Prevalence Research Group. Prevalence of Age-Related Macular Degeneration in the United States. Arch Ophthalmol. 2004; 122:564-572.

5.    Lighthouse International. How the Eye Works. 2003. http://www.visionconnection.org/Content/YourVision/Understanding Vision/HowtheEyeWorks/default.htm. Last updated July 13, 2004. Accessed July 21, 2004.

6.    Lighthouse International. How the Eye Works. 2003. http://www.visionconnection.org/Content/YourVision/Understanding Vision/HowtheEyeWorks/default.htm. Last updated July 13, 2004. Accessed July 21, 2004.

7.    National Eye Institute. National Plan for Eye and Vision Research: Low Vision and Blindness Rehabilitation. http://www.nei.nih.gov/strategicplanning/np_low.asp. Last updated June 2004. Accessed July 20, 2004.

8.    Sommer MD, MHS, Alfred, Vitamin A Deficiency Disorders: Origins of the Problem and Approaches to Its Control. The Johns Hopkins University Bloomberg School of Public Health, 2001. Available at: http://www.biotech-info.net/disorders.html. Last updated May 17, 2001. Accessed Sept. 20, 2004.

9.   Age-Related Eye Disease Study Research Group. A Randomized, Placebo-Controlled Clinical Trial of High-Dose Supplementation with Vitamins C and E, Beta Carotene and Zinc for Age-Related Macular Degeneration and Vision Loss: AREDS Report No. 8. Arch Ophthalmol. 2001;119:1417-1436.

10.  The Eye Disease Prevalence Research Group. Prevalence of Age-Related Macular Degeneration in the United States. Arch Ophthalmol. 2004; 122:564-572.

11.  The Eye Disease Prevalence Research Group. Prevalence of Age-Related Macular Degeneration in the United States. Arch Ophthalmol. 2004; 122:564-572.

12.  AMD Alliance International. AMD Information: Facts About AMD http://www.amdalliance.com/amd-information/facts_about_amd.html. 2003. Accessed August 19, 2004.

13.  Women's Eye Health Task Force at Schepens Eye Research Institute, Inc. Age-Related Macular Degeneration (AMD): Who Is At Risk for AMD? http://www.eri.harvard.edu/wehtf/AMD2.html. 2003. Accessed Sept. 20, 2004.

14.  Prevent Blindness America and National Eye Institute. Vision Problems in the U.S.: Prevalence of Adult Vision Impairment and Age-Related Eye Disease in America. 2002.

15.  Prevent Blindness America and National Eye Institute. Vision Problems in the U.S.: Prevalence of Adult Vision Impairment and Age-Related Eye Disease in America. 2002.

16.  The Eye Disease Prevalence Research Group. Prevalence of Age-Related Macular Degeneration in the United States. Arch Ophthalmol. 2004; 122:564-572.

17.   Hagemen GS, et.al. A common haplotype in the complement regulatory gene factor H (HF1/CFH) predisposes individuals to age-related macular degeneration. Proc Natl Acad Sci USA. 2005;Vol.102:7227-32.

18.  Klein RJ, et.al. Complement factor H polymorphism in age-related macular degeneration. Science. 2005;Vol.308:385-89

19.  Edwards AO, et.al. Complement factor H polymorphism and age-related macular degeneration. Science.2005;Vol.308:421-24

20.  Faye EE and Fischer M. Macular Degeneration: What it is. What causes it. What can be done. http://www.lighthouse.org/macular_degeneration.htm. 2002. Accessed June 3, 2004.

21.  Ferris FL, Fine SL, Hyman L. Age-Related Macular Degeneration and Blindness Due to Neovascular Maculopathy. Arch Ophthalmol. 1984; 102:1640-1642.

22.  Ferris FL, Fine SL, Hyman L. Age-Related Macular Degeneration and Blindness Due to Neovascular Maculopathy. Arch Ophthalmol. 1984; 102:1640-1642.

23.  Seddon, JM. Epidemiology of Age-Related Macular Degeneration. (AP Schachat, S Ryan eds.) Retina, 3rd ed. St. Louis, MO: Mosby; 2001; 1039-50.

24.   Klein R, et. al. The Five-Year Incidence and Progression of Age-Related Maculopathy: The Beaver Dam Eye Study. Ophthalmology. 1997;1047:7-21.

25.   Klein R, et. al. Prevalence of Age-Related Maculopathy: The Beaver Dam Eye Study. Ophthalmology. 1992;99:933-45.

26.   Age-Related Eye Disease Study Research Group. A Randomized, Placebo-Controlled Clinical Trial of High-Dose Supplementation with Vitamins C and E, Beta Carotene and Zinc for Age-Related Macular Degeneration and Vision Loss: AREDS Report No. 8. Arch Ophthalmol. 2001;119:1417-1436.

27.   Macular Photocoagulation Study Group. Laser Photocoagulation of Subfoveal Neovascular Lesions in Age-Related Macular Degeneration: Results of a Randomized Clinical Trial. Arch Ophthalmol. 1991;109:1220-1231.

28.   Margherio RR, Margherio AR, DeSantis ME. Laser treatments with verteporfin therapy and its potential impact on retinal practices. Retina. 2000;20:325-330.

29.   Haddad WM, Coscas G, Soubrane G. Eligibility for treatment and angiographic features at the early stage of exudative age related macular degeneration. Br J Ophthalmol. 2002; 86:663-669.

30.  Bressler NM. Age related macular degeneration. New hope for a common problem comes from photodynamic therapy. BMJ. 2000;321:1425-1427.

31.  Maguire MG. Natural History. (Burger JW, Fine SL, Maguire MG, eds.) Age-Related Macular Degeneration. St. Louis: Mosby: 1999;17-30.

32.  Maguire MG. Natural History. (Burger JW, Fine SL, Maguire MG, eds.) Age-Related Macular Degeneration. St. Louis: Mosby: 1999;17-30.

33.  Age-Related Eye Disease Study Research Group. A Randomized, Placebo-Controlled Clinical Trial of High-Dose Supplementation with Vitamins C and E, Beta Carotene and Zinc for Age-Related Macular Degeneration and Vision Loss: AREDS Report No. 8. Arch Ophthalmol. 2001;119:1417-1436.

34.  The Eye Disease Prevalence Research Group. Prevalence of Age-Related Macular Degeneration in the United States. Arch Ophthalmol. 2004; 122:564-572.

35.  Age-Related Eye Disease Study Research Group. A Randomized, Placebo-Controlled Clinical Trial of High-Dose Supplementation with Vitamins C and E, Beta Carotene and Zinc for Age-Related Macular Degeneration and Vision Loss: AREDS Report No. 8. Arch Ophthalmol. 2001;119:1417-1436. 30

36.  Age-Related Eye Disease Study Research Group. A Randomized, Placebo-Controlled, Clinical Trial of High-Dose Supplementation With Vitamins C and E, Beta Carotene, and Zinc for Age-Related Macular Degeneration and Vision Loss: AREDS Report No. 8. Arch Ophthalmol. 2001;119:1417-1436.

37.  Age-Related Eye Disease Study Research Group. A Randomized, Placebo-Controlled, Clinical Trial of High-Dose Supplementation With Vitamins C and E, Beta Carotene, and Zinc for Age-Related Macular Degeneration and Vision Loss: AREDS Report No. 8. Arch Ophthalmol. 2001;119:1417-1436.

38.  Ambati J, et. al. Age-Related Macular Degeneration: Etiology, Pathogenesis, and Therapeutic Strategies. Survey of Ophthalmology. Vol. 48, No. 3. May - June 2003.

39.  Ambati J, et. al. Age-Related Macular Degeneration: Etiology, Pathogenesis, and Therapeutic Strategies. Survey of Ophthalmology. Vol. 48, No. 3. May - June 2003.

40.  The Pink Sheet. Vol. 66. No. 027. Page 20. July 5, 2004.

41.  Ellwein L. National Eye Institute: Updating the Hu 1981 Estimates of the Economic Costs of Visual Disorders and Disabilities. http://www.nei.nih.gov/eyedata/hu_estimates.htm. April 2004. Accessed June 2, 2004.

42.  Prevent Blindness America and National Eye Institute. Vision Problems in the U.S.: Prevalence of Adult Vision Impairment and Age-Related Eye Disease in America. 2002.

43.  O'Neill C, et al. Age-Related Macular Degeneration: Cost-of-Illness Issues. Drugs & Aging. 2001: 18 (4).

44.  O'Neill C, et al. Age-Related Macular Degeneration: Cost-of-Illness Issues. Drugs & Aging. 2001: 18 (4).

45.   Bonastre J, et al. The Burden of Age-Related Macular Degeneration: Results of a Cohort Study in Two French Referral Centres. Pharmacoeconomics. 2003: 21 (3).

46.   O'Neill C, et al. Age-Related Macular Degeneration: Cost-of-Illness Issues. Drugs & Aging. 2001: 18 (4).

47.   O'Neill C, et al. Age-Related Macular Degeneration: Cost-of-Illness Issues. Drugs & Aging. 2001: 18 (4).

48.   Rosenthal BP, et al. Seeing the Whole Picture: Visual Function and Age-Related Macular Degeneration. 2003.

49.   Rosenthal BP, et al. Seeing the Whole Picture: Visual Function and Age-Related Macular Degeneration. 2003.

50.   Age-Related Eye Disease Study Research Group. National Eye Institute Visual Function Questionnaire in the Age-Related Eye Disease Study (AREDS): AREDS Report No. 10. Arch Ophthalmol. 2003; 121(2):211-217.

51.  Rosenthal BP, et al. Seeing the Whole Picture: Visual Function and Age-Related Macular Degeneration. 2003.

52.  Rosenthal BP, et al. Seeing the Whole Picture: Visual Function and Age-Related Macular Degeneration. 2003.

53.   Williams RA, Brody BL, Thomas RG Kaplan RM, Brown SI. The psychosocial impact of macular degeneration. Arch Ophthalmol. 1998; 116(4):514-520.

54.   Rosenthal BP, et al. Seeing the Whole Picture: Visual Function and Age-Related Macular Degeneration. 2003.

55.   Williams RA, Brody BL, Thomas RG Kaplan RM, Brown SI. The psychosocial impact of macular degeneration. Arch Ophthalmol. 1998; 116(4):514-520.

56.  Ferris FL, Fine SL, Hyman L. Age-Related Macular Degeneration and Blindness Due to Neovascular Maculopathy. Arch Ophthalmol. 1984; 102:1640-1642.

57.  Seddon, JM. Epidemiology of Age-Related Macular Degeneration. (AP Schachat, S Ryan eds.) Retina, 3rd ed. St. Louis, MO: Mosby; 2001; 1039-50.

58. Macular Photocoagulation Study Group. Laser Photocoagulation of Subfoveal Neovascular Lesions in Age-Related Macular Degeneration: Results of a Randomized Clinical Trial. Arch Ophthalmol. 1991;109:1220-1231.

59.  Age-Related Eye Disease Study Research Group. A Randomized, Placebo-Controlled Clinical Trial of High-Dose Supplementation with Vitamins C and E, Beta Carotene and Zinc for Age-Related Macular Degeneration and Vision Loss: AREDS Report No. 8. Arch Ophthalmol. 2001;119:1417-1436.

60.  Age-Related Eye Disease Study Research Group. A Randomized, Placebo-Controlled Clinical Trial of High-Dose Supplementation with Vitamins C and E, Beta Carotene and Zinc for Age-Related Macular Degeneration and Vision Loss: AREDS Report No. 8. Arch Ophthalmol. 2001;119:1417-1436.

61.  Age-Related Eye Disease Study Research Group. A Randomized, Placebo-Controlled Clinical Trial of High-Dose Supplementation with Vitamins C and E, Beta Carotene and Zinc for Age-Related Macular Degeneration and Vision Loss: AREDS Report No. 8. Arch Ophthalmol. 2001;119:1417-1436.

62.   Ambati J, et. al. Age-Related Macular Degeneration: Etiology, Pathogenesis, and Therapeutic Strategies. Survey of Ophthalmology. Vol. 48, No. 3. May - June 2003.

63.   Advanstar Medical Economics Publications. Confronting the Emerging Public Health Epidemic of Wet Age-Related Macular Degeneration: Highlights of a Roundtable Discussion of The Macula Society. Supplement to Ophthalmology Times. 2004.

64.   Advanstar Medical Economics Publications. Confronting the Emerging Public Health Epidemic of Wet Age-Related Macular Degeneration: Highlights of a Roundtable Discussion of The Macula Society. Supplement to Ophthalmology Times. 2004.t

Jointly sponsored in part by an unrestricted educational grant from Eyetech Pharmaceuticals, Inc. and Pfizer Ophthalmics, a division of Pfizer Inc.

The American Academy of Ophthalmology does not endorse products, drugs, companies or other organizations.